Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 803 results for "daiichi sankyo"

Pharma giant to take redeveloped former Avaya Campus in Jersey
Real Estate Weekly

Apotex, Inc. v. Daiichi Sankyo, Inc.

Drug Product and Patent(s)-in-Suit: Benicar┬« and Benicar┬« HCT (olmesartan medoxomil); U.S. Patent No. 6,878,703 (the 703 patent) Nature of the Case and Issue(s) Presented: Daiichi holds approved NDAs for Benicar and Benicar HCT. Daiichi listed ... JD Supra, 2 days ago
[x]  
BioPharma-Reporter.com

Daiichi Sankyo : Offers Assistance to Victims of the 2016 Kumamoto Earthquake

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Executive Officer, Vice ...
 4 Traders1 week ago Daiichi Sankyo: looming Benicar patent loss and large molecule focus prompted plant closure  BioPharma-Reporter.com3 weeks ago Daiichi Sankyo announces closure of its Hiratsuka Plant  Bio Spectrum Asia3 weeks ago Daiichi Sankyo to close down its DSCP Hiratsuka plant  PharmaBiz3 weeks ago
[x]  

Medical University, Daiichi Sankyo & Mitsubishi UFJ Capital to open innovation research to develop new capillary stem cells

National University Corporation Asahikawa Medical University, Daiichi Sankyo Company Limited and Mitsubishi UFJ Capital Co. Ltd. have announced that they will launch open innovation research to develop the new capillary stem cells (CapSCs) ...
 PharmaBiz3 weeks ago DAIICHI SANKYO : Commencement of First-in-Human Clinical Trial for New Molecular Targeting Drug, Co-Developed with The University of Tokyo and National Cancer Center, to Treat Malignant Lymphoma (Including Adult T-cell Leukemia-Lymphoma)  4 Traders3 weeks ago DAIICHI SANKYO : Open innovation research on new stem cells by Asahikawa Medical University, Daiichi Sankyo, and Mitsubishi UFJ Capital  4 Traders3 weeks ago Open innovation research on new stem cells by Asahikawa Medical University, Daiichi Sankyo, and Mitsubishi UFJ Capital  FirstWord Pharma3 weeks ago

Daiichi Sankyo reports positive phase 3 trial results of denosumab in patients with rheumatoid arthritis

Global pharmaceutical company, Daiichi Sankyo Company Limited, announced that phase 3 clinical trials for AMG 162 (denosumab), a gene recombinant drug for patients with rheumatoid arthritis, has achieved a major objective. The study conducted in ...
 PharmaBiz3 weeks ago Effient for Certain ACS-PCI Patients With STEMI and NSTE-ACS Supported by DAPT Guideline Update  Cardiac Interventions Today3 weeks ago DAIICHI SANKYO : Announces Phase 3 Clinical Trial Results for AMG 162 (denosumab) Rheumatoid Arthritis Treatment  4 Traders4 weeks ago Daiichi Sankyo Announces Phase 3 Clinical Trial Results for AMG 162 (denosumab) Rheumatoid Arthritis Treatment  FirstWord Pharma4 weeks ago

Daiichi Sankyo seeks Japanese approval for manufacturing & sales of narcotic analgesic hydromorphone HCl

Daiichi Sankyo Company, Limited (Daiichi Sankyo), a global pharmaceutical company, announced that the company has filed an application for the manufacture and sales in Japan of hydromorphone hydrochloride oral formulation (extended-release and ...
 PharmaBiz4 weeks ago DAIICHI SANKYO : Announces Application in Japan for Manufacturing and Sales Approval of Narcotic Analgesic Hydromorphone Hydrochloride  4 Traders4 weeks ago Daiichi Sankyo Announces Application in Japan for Manufacturing and Sales Approval of Narcotic Analgesic Hydromorphone Hydrochloride  FirstWord Pharma4 weeks ago

MolecularMD Has Obtained CE Marking of a Diagnostic Assay Developed for a Daiichi Sankyo, Inc. Phase II Clinical Trial

) - MolecularMD Corp., a molecular diagnostics company that accelerates oncology drug development by providing custom companion diagnostic solutions and supporting clinical trial services for targeted cancer therapies, has partnered with Daiichi ...
 Sys-Con Belgium3 days ago
[x]  
Proactive Investors USA

Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Carcinoma

Home ┬╗ Categories: Liver Cancer , News Daiichi Sankyo announced that the independent data monitoring committee of the METIV-Hepatocellular cancer (HCC) study conducted a planned interim assessment and it was determined the trial will continue to ...
 CancerConnect.com3 weeks ago BRIEF-Arqule Inc says Daiichi Sankyo and Arqule announce continuation of METIV-HCC phase 3 study of tivantinib in second-line hepatocellular carcinoma  Reuters UK1 month ago ArQule, Inc. and Daiichi Sankyo's tivantinib trial to continue  Proactive Investors USA1 month ago ArQule, Inc. and Daiichi Sankyo reveal tivantinib trial to continue after interim analysis  Proactive Investors USA1 month ago
[x]  

Daiichi Sankyo and partners to research on capillary stem cells

Daiichi Sankyo has entered into a research collaboration with Mitsubishi UFJ Capital and Asahikawa Medical University to develop new capillary stem cells (CapSCs) into a cell source for regenerative medicine and cell therapy. CapSCs have been ...
 Pharmaceutical Technology3 weeks ago
Contract Pharma

Portola Pharmaceuticals inks deal with Daiichi Sankyo to develop andexanet alfa with edoxaban

Portola Pharmaceuticals has entered into a clinical collaboration agreement with Daiichi Sankyo to develop andexanet alfa as an antidote for edoxaban, Daiichi Sankyo's Factor Xa inhibitor, in Japan. Portola is developing andexanet alfa, a U.S. Food ...
 Pharmaceutical Business Review3 weeks ago BRIEF-Portola signs agreement with Daiichi Sankyo to develop andexanet alfa as an antidote for edoxaban  Reuters UK3 weeks ago Portola Enters Into Clinical Collab with Daiichi Sankyo  Contract Pharma3 weeks ago
Global Information Inc

Global Hypertension Drugs Market 2016-2020 - Key Vendors are Actelion, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo Company, Novartis AG & Sanofi SA - Research and Markets

20
 Yahoo! Finance1 day ago Anaplastic Thyroid Cancer Pipeline Review, H1 2016 Featuring Daiichi Sankyo, Exelixis, Genelux, Immune Pharmaceuticals, Millennium Pharma, Novartis & Plexxikon - Research and Markets  4 Traders1 month ago Global Endocrinology Drugs Market to Set at CAGR of 6.69% Between 2016-2020: MarketResearchReports.biz  Digital Journal15 hours ago Cancer Pain Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Johnson & Johnson, Pfizer, Teikoku Seiyaku - Research and Markets  Digital Journal2 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - daiichi sankyo
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less